
==== Front
Clin Hematol Int
Clin Hematol Int
3084
Clinical Hematology International
2590-0048
SAABRON PRESS Website: Clinical Hematology International

38884110
117961
10.46989/001c.117961
Review Articles
Single-cell genomics-based immune and disease monitoring in blood malignancies
https://orcid.org/0000-0003-3264-1040
Rathgeber Anja C. Data curation Software 1 2 3
https://orcid.org/0000-0002-2916-2164
Ludwig Leif S. MD/PhD https://www.mdc-berlin.de/de/ludwig
Writing – review & editing 1 3
https://orcid.org/0000-0002-9060-0207
Penter Livius MD https://www.penterlab.org
Conceptualization Formal Analysis Methodology Writing – original draft 2 4
1 Berlin Institute for Medical Systems Biology Max Delbrück Center for Molecular Medicine https://ror.org/04p5ggc03
2 Department of Hematology, Oncology, and Tumorimmunology Charité - Universitätsmedizin Berlin https://ror.org/001w7jn25
3 Berlin Institute of Health at Charité - Universitätsmedizin Berlin https://ror.org/0493xsw21
4 BIH Biomedical Innovation Academy Berlin Institute of Health at Charité - Universitätsmedizin Berlin https://ror.org/0493xsw21
Corresponding author: Livius Penter Charité – Universitätsmedizin Berlin Augustenburger Platz 1 13353 Berlin Germany Telephone: +49 (0)30 450 553 615 Fax: +49 (0)30 450 553 914 Email: livius.penter@charite.de
14 6 2024
2024
6 2 Impact of Best Practice Medicine 6284
23 11 2023
25 12 2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Achieving long-term disease control using therapeutic immunomodulation is a long-standing concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic stem cell transplantation that continues to provide potentially curative treatment for otherwise challenging diagnoses, recent years have seen impressive progress in immunotherapies for leukemias and lymphomas with immune checkpoint blockade, bispecific monoclonal antibodies, and CAR T cell therapies. Despite their success, non-response, relapse, and immune toxicities remain frequent, thus prioritizing the elucidation of the underlying mechanisms and identifying predictive biomarkers. The increasing availability of single-cell genomic tools now provides a system’s immunology view to resolve the molecular and cellular mechanisms of immunotherapies at unprecedented resolution. Here, we review recent studies that leverage these technological advancements for tracking immune responses, the emergence of immune resistance, and toxicities. As single-cell immune monitoring tools evolve and become more accessible, we expect their wide adoption for routine clinical applications to catalyze more precise therapeutic steering of personal immune responses.

single cell sequencing
immune monitoring
immune checkpoint blockade
CAR T cell therapy
allogeneic hematopoietic stem cell transplantation
natural barcodes
==== Body
pmcIntroduction

Blood malignancies have long been at the forefront of the development of immunotherapies. Spanning from the first complete remissions achieved with allogeneic hematopoietic stem cell transplantation (HSCT)1,2 to the most recent successes with chimeric antigen receptor (CAR) T cell therapies,3,4 bispecific T cell engagers (BiTEs)5,6 or immune checkpoint blockade (ICB),7 the field continuously pioneers strategies for therapeutic immunomodulation.8–12 These discoveries have been paralleled by an equally dynamic development of approaches to classify, quantify, and surveil immune cell function, including their impact on the immunomodulation of malignant cell populations. These efforts are thereby also driven by the necessity to confidently monitor these immunological interventions, to identify modulating factors that contribute to their clinical activity or resistance and, likewise, to precisely steer individual therapies.

This has led to a diverse repertoire of monitoring tools that enable tracking of immune cell function at high resolution, including flow cytometry,13 mass cytometry,14 immune receptor repertoire sequencing,15,16 donor chimerism tracking17 or cytokine profiling.18 It has also motivated the expansion of sequencing tool kits to identify and track the genetics,19–21 epigenetics22,23 or transcriptional states24,25 of malignant cell populations in response to immunotherapies.

With the maturation of single-cell sequencing technologies and their ability to measure multiple classes of molecular features at the same time,26,27 the prospect of a unified single-cell immune and cancer monitoring assay to integrate many of these tools is increasingly within reach. While associated costs and the complexity of single-cell analysis remain relatively high, great strides have been made that foreshadow the routine application of single-cell genomics for unprecedented immune and disease monitoring in blood malignancies.

Approaches for immune and blood cancer cell monitoring

One of the main objectives for therapeutic monitoring of immune and malignant populations is to obtain real-time information on immunologic and cancer cell states to guide individual treatment decisions. An illustrative example is the serial quantification of donor chimerism and measurable residual disease (MRD) in the post-transplant course to steer immunosuppression and initiate early immunotherapeutic interventions like donor lymphocyte infusion (DLI) when an incipient relapse arises.28–31

At the cohort level, immune monitoring is used to gain deeper insights into the biology of immunomodulatory treatments through retrospective analyses of banked samples, to improve therapeutic efforts for future cohorts. For these systematic studies, four broad areas of research include i) the identification of predictive biomarkers for successful treatment or occurrence of adverse events, ii) elucidation of effects on immune cell populations induced by the treatment, irrespective of response (i.e., pharmacodynamics), iii) dissection of specific mechanisms that lead to responses or immune toxicities and iv) the discovery of processes that contribute to therapeutic resistance (Fig. 1).

228292 Figure 1. Individual and cohort-level immune monitoring.

Real-time monitoring of immune cell responses provides opportunities to monitor therapeutic effects and to detect the need for additional interventions to optimize an individual treatment approach. One such example is rapid immunosuppression tapering (IST) in the wake of worsening donor chimerism and incipient relapse (left). Retrospective cohort-level analyses are performed on banked sample collections to discover predictive biomarkers, pharmacodynamics, and mechanisms that drive responses, resistance, or emergence of immune toxicities to improve treatment approaches for future cohorts (right).

Most of these questions entail aspects of immune cell function and responses in cancer cells in a constant feedback loop and make their integrative analysis desirable. However, immune and malignant cells are often studied individually for practical reasons. This is an opportunity for single-cell technologies to improve current research approaches, as they can dissect molecular and cellular mechanisms at multiple levels from the same sample and dataset.

Immune cells

Immune function results from a highly dynamic and complex network of dozens of different cell types with complementary functions. Comprehensively monitoring these systems, therefore, requires obtaining information at several organizational levels, including i) immune cell type identity of the major cell lineages and their subsets, ii) the state and functional capacity of individual cells within these subsets, iii) immune cell receptor repertoires as the basis for antigen recognition, including T cell,32–34 B cell35 or Killer Ig-Like receptors36 (TCR, BCR, KIR), and iv) the environmental milieu immune cells exercise their function in, which may be modulated by direct interactions with adjacent cells or through indirect cellular communication (i.e., cytokines). Early single-cell immune phenotypic studies based their cell type annotation largely on the identification of gene expression clusters, which proved challenging to link to established flow cytometric definitions.37 This is increasingly overcome by utilizing single-cell atlases38–40 that provide a common framework for the annotation of single-cell RNA sequencing (scRNA-seq) profiles, or integration methods that enable cross-study comparison of single-cell datasets41–43 and allow the placing of single-cell sequencing results into context with flow cytometric data.

The introduction of 5’ scRNA-seq technologies in combination with the detection of oligonucleotide-conjugated antibodies (i.e., cellular indexing of transcriptomes and epitopes – ‘CITE-seq’)44,45 has provided a platform that enables to resolve most of these immunogenomic features with one assay. It is now routinely possible to obtain BCR and TCR repertoires of thousands of single cells, and most recently emerging technologies enable the identification of antigen-specific T cells directly through integration of tetra- and dextramer methods with scRNA-seq.46,47 Finally, the nascent field of spatial transcriptomics is starting to provide direct insight into immune cell interactions and higher levels of topical and neighborhood organization.48

Cancer cells

Surveillance of malignant cell populations follows three main questions that include i) the classification of malignant cells, ii) their sensitive identification, for example in the form of MRD and iii) tracking of genetic/molecular changes within the malignant populations during therapeutic pressure such as their clonal evolution or the emergence of specific somatic mutations that convey resistance to a given treatment.19,49 To some extent, these questions can be addressed with flow cytometry (i.e., phenotyping and MRD detection) through identifying leukemia-associated immune phenotypes (LAIP), but the most versatile and unambiguous approach is the detection of genetic markers through sequencing. The advantage of genetic markers (somatic nuclear DNA mutations, chromosomal copy number aberrations, and more recently mitochondrial DNA mutations50) is that they can be utilized for all three aspects of tumor cell monitoring and that their binary property (presence or absence) is highly accessible to automated computational analysis.

For the detection of such natural genetic barcodes with single-cell sequencing, the choices are DNA- and RNA-based platforms which come with their individual strengths and advantages.51 In general, DNA-based single-cell sequencing, especially amplicon-based strategies, can obtain genetic information in thousands of cells and may be combined with protein detection that can distinguish immune and cancer cell populations.20,52 On the other hand, RNA-based detection of natural barcodes is more challenging, and has varying degrees of success, as it is dependent on the expression levels of genes that harbor a genetic marker or are part of a region with structural chromosomal changes.53–56 Nevertheless, whole-transcriptome single-cell RNA sequencing has the advantage that it can also provide detailed information on other cellular characteristics such as transcriptionally defined cell states that cannot be resolved with surface marker expression or immune receptor sequences, which are currently not easily accessible with DNA-based sequencing. A potential solution is sequencing platforms that provide information on DNA- and RNA properties, which are currently still associated with very high costs, lower data quality compared to isolated DNA or RNA sequencing, and, often, lower throughput.

A growing number of clinical studies that have leveraged single-cell genomics platforms for immune cell monitoring evidence the strength of providing a multi-layered read-out of immune cell properties and blood cancer dynamics following therapeutic interventions.

Allogeneic HSCT

One of the most active areas of immune surveillance has been the study of immune reconstitution after allogeneic stem cell graft infusion and the identification of circulating immune cell populations that associate with graft-versus-leukemia (GvL) effects or graft-versus-host-disease (GvHD) using flow cytometry57,58 or mass cytometry.59,60 Single-cell genomics studies are now deepening our understanding of these processes, as they additionally resolve transcriptional states, immune receptor repertoires and single-cell donor/recipient origin61 of the involved immune cells. Further, single-cell studies are starting to shed light on immune cell dynamics and donor immune contributions in GvHD target tissues, such as skin or the gastrointestinal (GI) tract, which have previously been far less studied, due to technical limitations, such as the inability to distinguish donor- from recipient-derived single cells (Fig. 2).62

228293 Figure 2. Single-cell tools for immune monitoring after allogeneic hematopoietic stem cell transplantation (HSCT).

Single-cell transcriptomics provides insight into cell identities and functional states. Through B cell and T cell receptor (BCR, TCR) sequencing and deconvolution of donor- and recipient-derived cells, and leveraging expressed germline single nucleotide polymorphisms (SNPs) or mitochondrial DNA mutations, processes such as immune reconstitution, graft-versus-leukemia (GvL) effects and graft-versus-host disease (GvHD) can be dissected at high resolution.

Immune reconstitution after transplant

Fundamental groundwork for a more complete understanding of post-HSCT immune reconstitution has been laid by Huo et al,. who performed scRNA-seq on serially collected bone marrow and peripheral blood samples of 10 patients undergoing transplant for aplastic anemia.63 By sequencing FACS-sorted CD34+ cells, they documented a proliferative burst of hematopoietic stem cells with skewing towards megakaryocyte-erythroid progenitors, in the first week after graft infusion, followed by a gradual normalization of transcriptional states to a physiologic output of progenitor differentiation until day 30, that was similar across all 10 study subjects. In contrast, scRNA-seq of unsorted populations demonstrated the heterogeneity of circulating immune cell reconstitution following day 30, with large differences in the ratios of monocytes, B and T cells. Another study on immune reconstitution post-HSCT by Obermayer et al. monitored T cell reconstitution and TCR repertoires in 5 patients undergoing myeloablative transplant, and found persistence of expanded donor-derived CD8+ effector memory T cell clones following graft infusion into the host.64 Finally, Luo et al. have explored the heterogeneous landscape of regulatory T cells (Tregs), and compared their transcriptional states in the post-transplant context with those from healthy donors, which revealed both shared and distinct gene expression profiles.65 Together, these studies confirm previously known dynamics of immune reconstitution following allogeneic HSCT, provide refined insights into transcriptional states and TCR repertoires and establish a framework for future scRNA-seq analyses on post-transplant immune reconstitution.

Graft-versus-host disease

In contrast to the ready availability of circulating immune cells, technical hurdles in the past have made the study of GvHD in primary human tissue biopsies much more challenging than in peripheral blood. This was due to the lack of high-throughput approaches to distinguish donor from recipient-derived single cells. Single-cell transcriptomics solves several challenges and now enables to address questions such as i) the contribution of donor-derived immunity to tissue-resident memory populations, ii) the persistence of host-derived immunity in GvHD target tissues and, iii) differences in the phenotypes of tissue-resident memory compared to circulating immune cells. This advancement is highly relevant for understanding the mechanisms driving off-target alloreactivity since the study of tissue-resident T cells, which vastly (>10x) outnumber circulating T cells,66 requires investigation of primary human tissue biopsies.

In the first scRNA-seq study of post-transplant tissue-resident T cells, Strobl et al. systematically dissected tissue chimerism and the phenotypes of skin T cells based on a dedicated longitudinal sample collection of tissue biopsies and matched peripheral blood samples before and at multiple time points post-HSCT.67 With an analysis that leveraged expression of single nucleotide polymorphisms68 and de-novo reconstruction of TCR sequences,69 they demonstrated the co-existence of donor- and recipient-derived T cells in two patients on day 14 after the transplant. They extended this analysis further and provided examples of persistent high recipient T cell chimerism in skin biopsies for up to ten years post-HSCT using X/Y fluorescence in situ hybridization (FISH).

Using scRNA-seq, Almeida et al. have confirmed the longevity of host-derived skin-resident T cells following allogeneic transplant with myeloablative conditioning (MAC) despite complete donor T cell chimerism in the blood in two more cases, and demonstrated that host tissue-resident T cells circulated in peripheral blood after transplant with retained expression of tissue-specific gene expression profiles and tissue-residency markers such as BLIMP1 and LGALS3.70 However, these observations were not identified in all 26 patients, as only 6 had incomplete skin donor chimerism. Further, the authors of that work did not find evidence of host skin-resident T cells as drivers of skin GvHD, as suggested by other studies.62,67

A study by Jarosch et al. characterized gastrointestinal (GI) biopsies via scRNA-seq combined with scTCR-seq and found an increase in Tregs and clonally expanded CD8+ T cells to be associated with severe acute GvHD. The clonally expanded CD8+ T cells were shared across different GI biopsies from the same individuals, suggesting they are drivers of GvHD. Deorphanizing their antigen specificity would be highly informative for a deeper understanding of the mechanisms underlying GI GvHD and alloreactivity in general.

Together, these studies provide first glimpses into the very incompletely understood phenotypes and TCR repertoires of tissue-resident memory T cells in GvHD. Much remains to be explored, such as the exact trajectory of alloreactive T cells from graft infusion into target tissues or whether their phenotypes and TCR repertoires differ across tissue compartments. The latter question has recently been addressed by DeWolf et al. in a systematic study of TCR repertoires across multiple different tissue sites.71 The authors identified anatomically defined TCR repertoires and motifs that only partially overlapped with circulating TCR repertoires, underscoring the importance of the study of tissue-resident memory T cells. Besides providing a deeper understanding of T cells, scRNA-seq studies of tissue biopsies should also investigate the role of other cell types in the pathogenesis of GvHD, such as B cells, for which Poe et al. have provided a baseline by defining their transcriptional profiles in peripheral blood and bone marrow.72 The possibilities of spatial transcriptomics in combination with the detection of immune cell receptor sequences73,74 will enable the mapping of alloreactive cells to their cellular targets, and further refine our understanding of GvHD.

Graft-versus-leukemia effects

Despite decade-long research on GvL effects, it still remains incompletely understood what cellular mechanisms determine protective alloreactivity against disease recurrence, and how they fail when relapse occurs.75 Single-cell studies are providing opportunities to address these questions from a fresh angle while leveraging deep sample archives. Despite practice changes in treatments, such as the introduction of tyrosine-kinase inhibitors for BCR::ABL1+ in chronic myeloid leukemia (CML), or Bruton tyrosine kinase (BTK) and BCL2 inhibitors for chronic lymphocytic leukemia (CLL), these longitudinal sample collections remain highly relevant for translational immunologic research.76 The fact that donor selection, conditioning regimens and immunosuppression are precisely defined, makes allogeneic transplantation an attractive clinical model for immunotherapy. As such, samples from CML and CLL cases pre- and post-transplant provide opportunities to dissect general mechanisms of GvL that can serve as a framework for improving transplant outcomes for other blood malignancies and may reveal general concepts applicable to other immunotherapies.

In one study, Bachireddy et al. investigated resistance mechanisms to GvL by studying matched CLL relapse samples before and following reduced intensity conditioning (RIC)-HSCT using whole-exome sequencing (WES) and scRNA-seq, focusing on genetic and transcriptional changes in cases with early versus those with late relapse post-HSCT. While early post-transplant relapse cases demonstrated genetic and transcriptional stability, late relapse cases were characterized by clonal evolution at the genetic and transcriptional level, likely due to a more sustained immune pressure by GvL.77 These GvL-induced changes were heterogeneous and suggest diverging immune escape mechanisms.

In a second mechanistic study on GvL, Bachireddy et al. tracked the dynamics of T cell subsets in 6 responders and 6 non-responders to CD8+ T cell-depleted DLI for relapsed CML post-HSCT using scRNA-seq and bulk assay for transposase accessible chromatin with high-throughput sequencing (ATAC-seq). Consistent with a prior study on DLI in CML,78 they observed enrichment of exhausted T cells in responders compared to non-responders prior to DLI. Integration of scRNA-seq with bulk ATAC-seq data demonstrated the role of transcription factor master regulators such as TOX in T-cell exhaustion. Infusion of DLI led to a contraction of exhausted T cell clusters, but this was largely driven by T cell clones which were detectable before DLI and not those that were uniquely provided by the DLI product, suggesting a mechanism of immunologic support rather than direct provision of CML-specific effector T cells.

These results contrast with analyses on the determinants of successful DLI in acute myeloid leukemia (AML), where Maurer et al. have observed the expansion of cytotoxic CD8+ T cells in concert with naïve B and other cell populations after infusion, suggesting diverging underlying mechanisms.79 Non-response was associated with increased expression of KLRG1 and TIGIT, which is similar to another recent study that identified TIGIT as an important indicator of post-transplant AML relapse.59,80 In a study of post-transplant relapse of pediatric AML, Shahid et al. found downregulation of HLA class II expression,81 confirming observations from adult AML.24,25

Immune checkpoint blockade in AML relapse

Myelodysplastic syndrome (MDS) and AML are currently the most frequent indications for allogeneic HSCT in adult hematology, which can improve long-term survival in high-risk cases.82,83 However, relapse is still frequent and, therefore, a distinct clinical need exists for strategies that improve anti-leukemic immune responses for AML/MDS. Early experiences with immune checkpoint blockade (ICB) in AML/MDS, such as durable remissions in post-transplant leukemia cutis relapse cases following CTLA-4 blockade (ipilimumab)84,85 or favorable associations of pretreatment T cell infiltration with clinical activity of PD-1 blockade (nivolumab) in combination with azacytidine86 generated a lot of interest to utilize ICB to address post-transplant and transplant-naïve AML relapse (Fig. 3).

228294 Figure 3. Mechanisms of immune checkpoint blockade activity in acute myeloid leukemia (AML).

Ipilimumab has shown durable remissions in extramedullary acute myeloid leukemia (eAML) with skin manifestation (leukemia cutis) likely due to high infiltration of Tregs that express CTLA-4. In bone marrow, inhibition of PD-1 is rationalized by overexpression of PD-L1 in JAK2V617F-mutated AML. TIM3 is expressed by natural killer (NK) and exhausted T cells, providing a mechanistic base for TIM3 inhibition. ICB-induced off-target toxicity is associated with activation of effector memory T cells in peripheral tissues. This has limited the use of PD-1 blockade in the post-transplant setting due to intolerable rates of graft-versus-host disease (GvHD).

This was further supported by murine data that demonstrated overexpression of PD-L1 in JAK2V617F-mutated myeloproliferative neoplasms (MPN) as an actionable immune escape mechanism.87 Penter et al. dissected an index case of a secondary JAK2V617F-mutated AML relapse post-HSCT who received nivolumab based on this rationale, using a multi-omics single-cell approach.88 The authors observed an expansion of CD4+ T cells after nivolumab infusion that was paralleled by the contraction of a megakaryocytic leukemic cell population characterized by PD-L1 expression. This megakaryocytic population later recovered at the time of AML progression, when the CD4+ T cell population contracted again, consistent with immune evasion of leukemia cells following an activated CD4+ T cell GvL response. Tregs progressively expanded within the CD4+ T cell compartment during PD-1 inhibition, which may be a potential counter mechanism after PD-1 inhibition.

Although later clinical results do not support ICB as a generally effective immunotherapy in myeloid disease,89–92 several clinical studies that tested this approach have been accompanied by single-cell sequencing-based immune monitoring efforts. These have provided instructive vignettes on tumor immunology in AML and have been able to explore more index cases with exceptional responses to ICB, providing starting points for future investigations in the development of immunotherapies for AML/MDS.

CTLA-4

The observation of durable remissions in post-transplant leukemia cutis relapse following ipilimumab infusion led to the ETCTN/CTEP 10026 study, which tested the hypothesis that an alloreactive environment would enhance clinical activity of ICB. Unexpectedly, the overall response rate to combined decitabine and ipilimumab on ETCTN 10026, which recruited mostly bone marrow-involved AML/MDS, was higher in the transplant-naïve compared to the post-transplant arm, and responses were short-lived.93 Large-scale scRNA-seq analyses of 64 bone marrow samples from 18 patients showed that CTLA-4 blockade increased the percentage of Tregs, likely as a compensatory mechanism to ipilimumab infusion, and demonstrated that the short duration of responses was associated with insufficient clearing of leukemic clones from progenitor cells.

Durable remissions observed with CTLA-4 blockade in extramedullary AML, and the higher activity of ipilimumab in cancers such as metastatic melanoma, prompted additional investigations into immunologic differences between bone marrow-involved AML, leukemia cutis and solid malignancies. Compared to scRNA-seq data of T cells from solid malignancies, AML bone marrow cell profiles had much fewer features of T cell exhaustion. A comparative analysis by bulk RNA-seq revealed higher infiltration of CTLA-4+ T cells in extramedullary versus bone marrow-involved AML.94 Interestingly, one exceptional post-transplant responder with bone marrow disease had an ongoing response for more than 3 years after combined decitabine and ipilimumab treatment. In that case, the pretreatment bone marrow was heavily infiltrated by CTLA-4+ and PD-1+ T cells, suggesting a preexisting GvL response whose clinical activity was further enhanced by ipilimumab. Overall, this study indicates that extramedullary AML associates with immunologic features that confer susceptibility to immunotherapy and provides opportunities for therapeutic targeting that should be further investigated. One such potential research direction has been proposed by Koedijk et al., who have used spatial analyses to demonstrate the existence of large T cell networks that associate with response to CTLA-4 blockade, and could represent a marker of susceptibility to immunotherapy.95

PD-1

Several studies with diverging insights illustrate that the mechanisms of response to PD-1 inhibition in AML seem to be heterogeneous.

Apostolova et al. reported signatures of higher T cell activation and lower senescence in CD8+ T cells that distinguished responders from non-responders to combined decitabine/azacytidine and nivolumab treatment.96 In one notable study participant, who maintained an incomplete remission (CRi) for 11 months after discontinuing nivolumab, scRNA-seq revealed signs of distinct immune activation with donor-derived monocytes which had high expression of HLA class II molecules. These observations provide evidence of nivolumab-induced immune activation as the driver for the observed reinvigorated GvL activity.

In contrast, Goswami and Gui et al. observed clonal expansion of activated effector T cells with expression of markers such as HLA-DR, PD-1 and TIM-3 in three non-responders who experienced immune toxicities (central diabetes insipidus and hypothyroidism) after combined treatment with decitabine and the PD-1 blocking antibody pembrolizumab.97 This suggests these expanding T cell clones are involved in the reported adverse events and opens up the question about their antigen specificity, given that hypothyroidism is a frequent toxicity of therapeutic PD-1 blockade. Remarkably, unlike in study participants with immune-related adverse events, the authors failed to observe T-cell clonality or phenotype changes in two responders, illustrating difficulties in disentangling decitabine- from nivolumab-induced therapeutic effects.

In another study, Abbas et al. investigated 22 serial samples of 8 study participants who received azacytidine and nivolumab. AML cases were characterized by higher clonal T cell expansion compared to two healthy donors. They displayed diverging dynamics of changes in clonal expansion between responders and non-responders during PD-1 inhibition. In one notable responder case, loss of chromosome 7 developed following response to nivolumab-based treatment and could have represented an immune resistance mechanism in that case.

Together, these analyses represent illustrative examples of how single-cell genomics of samples obtained from clinical studies can provide deep and integrative immune and AML monitoring.

TIM-3

TIM-3 is a third immune checkpoint molecule whose inhibition is being investigated in AML/MDS98,99 with opportunities for correlative immunologic studies. Huuhtanen et al. have presented initial analyses into responses to TIM-3 inhibition in AML.100 Their systematic reanalysis of 500,000 scRNA-seq profiles across 160 bone marrow aspirates showed higher TIM-3 expression levels in activated T cells and hematopoietic stem cells (HSCs) in individuals with blood malignancies compared to healthy donors, underscoring a rationale for therapeutic TIM-3 inhibition. Interestingly, NK cells also have high TIM-3 expression, suggesting that they may play an important role in the clinical activity of TIM-3 inhibitors, which may be especially relevant for the early post-transplant context, due to the faster NK immune cell reconstitution compared to T cells.58

CAR T cell therapy

One of the most significant developments in immunotherapies for blood malignancies has undoubtedly been the introduction of CAR T cell therapy directed against the B cell lineage markers CD19 and B-cell maturation antigen (BCMA).101,102 The wide expression of these markers on malignant B cells that are the foundation for fast and deep remissions have enabled the impressive clinical success of this therapeutic strategy. Nevertheless, relapse still occurs frequently even with CAR T cell therapy, and only about 50% of patients achieve a sustained complete remission. This has motivated many single-cell genomics-based immune monitoring studies to investigate the determinants of successful CAR T cell therapy and mechanisms driving resistance. Finally, although generally manageable, on-target off-tumor long-term toxicities following CAR T cell infusion (i.e., sustained B cell aplasia) are another important area of research, and studies identifying molecular features of adverse events, such as acute neurotoxicity which often occurs within days of CAR T cell infusion, are now emerging.

CD19

CAR T cell therapy against CD19 is certainly the model for a broadly applicable cellular therapy with a profound impact on treatment outcomes in many B cell malignancies. The success of this therapy has also led to large single-cell sequencing immune monitoring studies to define its optimal use. These studies focus on molecular and cellular features that are associated with early aspects of CD19 CAR T cell therapy (i.e., manufacturing processes and cellular dynamics immediately following infusion), medium- or long-term aspects (mechanisms mediating disease relapse, persistence of CAR T cells) or adverse immune toxicities. Together, they have provided us with precise insights into the phenotypes of CAR T cells that constitute starting points for improvements in the development of this cellular therapy (Fig. 4).

228295 Figure 4. Examples of mechanistic insights on CD19-directed CAR T cell therapy gained through single-cell RNA sequencing studies.

Single-cell studies were focused on T cell states of CAR infusion products (pre-infusion), short-term effects that lead to response, resistance, or occurrence of immune-related toxicities in the immediate days after infusion (short-term) and mid- or long-term effects of CAR T cell therapy.

Several studies have focused on transcriptional profiles of infusion products as biomarkers for response. For example, Deng et al. found that response to axicabtagene ciloleucel (axi-cel) in large B cell lymphomas (LBCLs) was associated with fewer exhausted T cells and higher frequencies of memory T cells.103 This was consistent with results from a study by Chen et al., who found that apheresis products with higher proportions of naïve, stem cell memory and central memory T cells were associated with CAR T cell persistence beyond 6 months ,104 and with results from Saren et al., who found polyfunctional effector-like CD8+ T cells to associate with clinical response.105

Finally, Bai et al. identified a deficiency in T helper 2 function that was associated with relapse in a study of 12 CAR infusion products.106 Together, these results indicate that manufacturing of CAR T cell infusion products should take into consideration apheresed T cell states, for example by enriching for naïve and other less differentiated subsets. They also suggest that allogeneic CAR T cell products from healthy donors may be advantageous for higher clinical efficacy.107

By screening published scRNA-seq data of CAR T cell infusion products, Lareau et al. made the remarkable observation that the manufacturing process likely leads to reactivation of HHV-6 in rare cases (28 out of 819,321 screened cells).108 This constitutes a potential source for fatal CNS HHV-6 infections that have been observed after CAR T cell therapy.109–112

Going beyond the CAR T cell manufacturing process, Sheih et al. performed short-term tracking of CAR T cells from infusion products and peripheral blood up to 112 days after infusion.113 They observed a large polyclonal expansion of CD8+ CAR T cells within the first 10 days post-infusion and a progressive change in transcriptional state. Initially, CAR T cells displayed gene expression profile with features driven by the high metabolic activity manufacturing process that changed over time to a less activated transcriptomic state.

Dissection of transcriptional states in CAR infusion products and their short-term longitudinal dynamics after infusion were further refined by Haradhvala, Leick & Maurer et al. who addressed the question of whether axi-cel and tisagenlecleucel (tisa-cel) have different mechanisms of response and resistance. They performed scRNA-seq on both CAR products, matched circulating CAR T cells at day 7 after infusion, and found marked differences in their composition and post-infusion cellular dynamics.114 While axi-cel infusion products contained variable amounts of CD8+ T cells, tisa-cel contained very few CD8+ T cells that rapidly expanded by day 7, driven by the most expanded clones in the infusion product. On the other hand, the proliferation of tisa-cel CD4+ CAR T cells very quickly stopped after infusion. Transcriptional profiles of CAR T cells differed by product, such that, for example, CD28 signaling of axi-cel associated with higher PD-1 expression at day 7.

Both studies found that individual CAR T cell clones identified by their native TCR sequence changed in frequency and phenotype over time, illustrating that the population of infused CAR T cells continues to evolve, likely due to sustained interaction with their target antigen, either from recovering physiologic B cell lymphopoiesis or minimal residual disease.

Further evidence for the continued evolution of CAR T cells, but also their remarkable in-vivo longevity, has been documented by a scRNA-seq study that showed the persistence of proliferative CD4+ CAR T cells for more than 10 years in two patients with sustained CLL remission and B cell aplasia.115 In a second scRNA-seq study on the long-term persistence of CAR T cells in 15 pediatric ALL patients, Anderson et al. observed that CAR T populations were increasingly dominated by CD4/CD8 double-negative cells more than one year after infusion. They were able to define a signature of long-term CAR T cell persistence including expression of the immune checkpoint molecule TIGIT or the effector molecule GZMK. Through analysis of native TCR sequences expressed by CAR T cells, they could demonstrate that CAR T cell populations remain highly polyclonal even years after infusion.116

Multiple scRNA-seq studies have found mechanisms of non-response and relapse after CD19 CAR therapy, which can be categorized as a result of immune escape by tumor cells (i.e., loss of the target antigen CD19) or suboptimal CAR T cell function.

CD19-negative disease relapse after CD19-directed CAR T cell therapy is frequent and one of the clinically most relevant resistance mechanisms, as it renders re-exposure to CAR T cells futile.110,117 Multiple mechanisms of CD19 downregulation have been described.118–122 However, it is not fully understood whether tumor cells with low CD19 expression generally exist prior to CAR T cell infusion or whether the loss of CD19 expression develops de-novo under therapeutic pressure. Im et al. investigated this question through in-vitro analyses and found that interactions between CAR T cells and tumor cells lead to a sustained downregulation of surface CD19 expression through internalization, arguing against preexisting CD19-negative tumor cells.123 In contrast, Rabilloud et al. dissected one case of CD19-negative ALL relapse after CAR with the help of scRNA-seq, and could show that this was due to the expression of a non-functional CD19 isoform in ALL cells, which were detectable even prior to CAR T cell therapy. This suggests that screening for CD19-negative ALL cells prior to infusion may help to anticipate disease relapse in at least a faction of cases.124

Besides the loss of the target antigen CD19, several immune resistance mechanisms to CD19 CAR T cell therapy have been found. The study by Haradhvala et al. identified CAR Tregs which were detectable in both infusion products (axi-cel and tisa-cel) and associated with non-response and relapse to CD19 CAR T cell therapy. A second study by Good et al. linked CAR Tregs to therapeutic resistance through inhibition of CD8+ CAR T cell expansion (axi-cel) after infusion in 32 cases of large B cell lymphoma (LBCL).125 This finding was consistent across both studies, and suggests a potential strategy for improvement of the CAR T cell manufacturing process through the depletion of CAR Tregs from infusion products.

Increased expression of the immune checkpoint molecule TIGIT on circulating CAR T cells is another resistance mechanism identified using two scRNA-seq studies.126,127 Jackson et al. immunophenotyped 4-1BB CAR T cells from 14 manufacturing products and from 27 peripheral blood samples 14 to 30 days after infusion in 13 non-Hodgkin lymphoma (NHL) cases.127 They found circulating CAR T cells to express higher TIGIT levels in non-responders, and could validate the relevance of this finding in an in-vivo model in which TIGIT blockade led to longer survival of mice challenged with lymphoma cells and CAR T cells.

In contrast, by tracking SJCAR19 CAR T cells longitudinally in 16 pediatric B-acute lymphoblastic leukemia (ALL) cases before and up to 6 months after infusion using their native TCR sequences as clonal barcodes, Wilson et al. found that TIGIT expressing effector precursor CD8+ CAR T cells constitute a subpopulation within infusion products that has superior functionality and is less prone to acquire an exhausted phenotype.128

These apparent discrepancies may relate to the different CAR T cell products investigated, but also inherent differences of the pediatric or adult setting, including prior therapies. This illustrates an opportunity for integrative data reanalysis across the different studies to understand better commonalities and differences of CD19 CAR T cell therapies in different contexts.

Finally, single-cell studies are starting to identify factors associated with adverse events after CAR T cell infusion, such as neurotoxicity, a potentially life-threatening adverse event that occurs in a substantial percentage of cases (38-77%)129,130 or prolonged cytopenias. The study by Good et al. found CAR Tregs to be protective against the occurrence of immune effector cell-associated neurotoxicity syndrome (ICANS).125 The fact that CAR Tregs were also associated with disease progression indicates that future studies could focus on identifying an optimal level of their frequency in CAR T cell products to reduce ICANS while retaining disease control, similar to efforts of fine-tuning GvL and GvHD after transplant.

Strati et al. identified clonally expanded CX3CR1hi cytotoxic T cells associated with prolonged cytopenia after axi-cel CAR T cell infusion in a study of 16 LBCL cases.131 These T cells also included clones that did not express a CAR transcript, raising the possibility of cross-talk between CAR and non-CAR T cell populations. Deorphanizing TCR antigen specificities of scRNA-seq studies that identify associations of immune toxicities with expanded T cell populations would be very valuable.

BCMA

Targeting BCMA for multiple myeloma is a second CAR T cell therapy that has gained a lot of traction in recent years,132,133 with emerging single-cell genomics studies starting to better define determinants of response and resistance to BCMA CAR.

Similar to CD19- relapse, targeting BCMA via CAR T cell therapy can lead to loss of the target antigen. Two scRNA-seq studies have investigated the underlying genetics and showed this to arise due to a biallelic loss of BCMA.134,135 Other mechanisms that lead to BCMA loss include missense and frameshift mutations.136 Although heterozygous loss of BCMA is frequent in multiple myeloma before CAR T cell infusion, BCMA loss as a resistance-driving mechanism is nevertheless less common than CD19- relapse after CD19 CAR.137 Single-cell RNA sequencing studies are also emerging to define immune-related toxicity after BCMA CAR T cell infusion, for example, in a case of sarcoidosis-like disease138 and cellular dynamics associated with response and resistance in individual cases.139,140 This includes a study on immune-cell correlates with response to BCMA CAR by Dhodapkar et al. that provides the first glimpses into the long-term effects of this therapeutic approach.141

In the coming years, a wealth of studies will undoubtedly be forthcoming that will investigate immune cell correlates of response, resistance, and toxicities to BCMA CAR. The body of work in the field of CD19-directed CAR T cell therapy will be a useful framework for this.

Tracking cancer cell evolution using natural genetic barcodes

Besides pioneering immunotherapy and methods for monitoring immune responses, blood malignancies have been models for the longitudinal study of genetic evolution that leads to malignant transformation, underpins acquisition resistance following immunotherapeutic interventions and drives secondary transformation from low- to high-grade disease states (Fig. 5). Single-cell sequencing approaches have become valuable tools for dissection of these processes, which are transforming our understanding of clonal relationships between physiologic and malignant hematopoiesis. These studies herald the adoption of single-cell sequencing as a clinical tool for monitoring therapeutic responses or acquisition of resistance at high resolution.

228296 Figure 5. Tracking of clonal evolution using somatic nuclear and mitochondrial DNA mutations.

Somatic nuclear mutations are an established approach for tracking clonal evolution from premalignant clonal expansion to blood cancer and to transformed disease. In comparison to mitochondrial DNA (mtDNA), nuclear genomic DNA has a lower mutation rate and generally only 2 copies per cell, which makes attaining sufficient coverage for variant calling with single-cell sequencing approaches challenging. The high mutation rate of mtDNA and the better genomic capture at single-cell resolution potentially enable the higher-resolution tracking of clonal hierarchies, while the integration of both approaches is further maturing.

CHIP – clonal hematopoiesis of indeterminate potential, MBL – monoclonal B lymphocytosis, MGUS – monoclonal gammopathy of undetermined significance, AML – acute myeloid leukemia, CLL – chronic lymphocytic leukemia, MM – multiple myeloma, RS – Richter’s syndrome, eAML – extramedullary AML

WGS – whole-genome sequencing, WES – whole exome sequencing

scDNA-seq – single-cell DNA sequencing

Somatic nuclear mutations

Amongst all genetic markers that enable tracking blood malignancies, somatic single nucleotide variants (SNVs) represent arguably the best-studied class, due to their high frequency142 and ease of detection. SNVs arise from endogenous processes like DNA replication error but also from exogenous causes such as exposure to toxic environmental factors.143 Their occurrence is associated with premalignant states such as clonal hematopoiesis of indeterminate potential (CHIP),144 monoclonal B cell lymphocytosis (MBL)145 or monoclonal gammopathy of undetermined significance (MGUS),146 and ultimately development of cancer.

The documentation of the full genetic landscape of blood malignancies in newly diagnosed or relapsed diseases was enabled by whole exome sequencing (WES) and whole genome sequencing (WGS) in combination with systematic blood and bone marrow banking programs. Major fundamental works included large-scale genetic characterizations of MBL/CLL,147,148 the genomic classification of AML,149 ALL150 and B cell lymphomas like MM151 or diffuse large-cell lymphoma.152 WES has also established the relationships between premalignant states and blood cancer. CLL and AML were found to genetically resemble their precursor conditions,153–157 while MM has been characterized to harbor increased genetic complexity compared to MGUS.158 These foundational studies have provided major insights into pathogenesis and prognostication in blood malignancies, insights which have profoundly changed their risk stratification and therapeutic approaches. Moreover, they are the starting point for many contemporary single-cell genomics studies.

Longitudinal analyses of matched samples from initial diagnosis and relapse have further established the concept of clonal evolution following therapeutic bottlenecks that give rise to increasingly selected and resistant leukemia clones. Due to the decade-long natural disease history and the numerous consecutive treatments, CLL has been one of the model systems for the study of clonal evolution.147,159,160 In AML, longitudinal genetic studies have established diverging patterns of resistance to therapy, including persistence and further linear evolution of a founding clone, or outgrowth of a branch of subclones that replace the founder.161,162 These insights have also sparked investigations into the clonal dynamics of malignancies for which tumor cells are more difficult to obtain, such as MM or Hodgkin’s lymphoma163 that have documented evolution towards increased genetic complexity following therapeutic bottlenecks.164,165 Together, they have motivated deeper elucidation of subclonal heterogeneity at the single-cell level.

With single-cell sequencing (scSeq) experiencing its “breakthrough” in 2018 (https://vis.sciencemag.org/breakthrough2018/finalists/), genetic studies in blood malignancies can now be conducted at truly high resolution. In bulk WGS/WES data, variant allele fractions (VAF) can generally be confidentially called down to 0.1-1% due to amplification or sequencing artifacts that may reach VAFs of 0.1-1%.166 A further challenge of bulk sequencing data analysis is the imputation of clonal heterogeneities from VAFs. With scDNA-seq, these boundaries have been profoundly shifted: clonal substructures can be directly observed at the level of individual single cells. Further, malignant clones can be tracked across cell types, which resolves clonal hierarchies between progenitor and differentiated cell compartments. Finally, it is possible to distinguish somatic mutations that are expanded within tumor cells from those in unrelated immune cells without sophisticated sequencing of sorted bulk populations.167

The technical improvements of single-cell sequencing have provided direct evidence of clonal competition, but are also enabling the tracking of individual rare malignant cells. For example, an early targeted scDNA-seq study of two AML cases by Pellegrino et al. documented the persistence of leukemia cells at the time of remission and their clonal heterogeneity.168 Miles et al. utilized this approach systematically by sequencing 143 samples from 123 patients based on the detection of 31 recurrent somatic mutations, and tracked co-existing AML subclones back to their origin in MPN.52 Morita et al. similarly tracked mutational histories in 154 samples from 123 AML cases and provided insight into clonal competition and selection of resistance clones during therapy such as FLT3 inhibition.20 The concepts of clonal competition and evolution have also been studied in other blood malignancies including B150 and T-ALL,169,170 CLL171 or MM.172–174

Together, these studies showcase the potential of single-cell sequencing for the clinical tracking of the emergence of disease resistance during therapy, including in the setting of MRD. In the context of allogeneic HSCT, the detection of MRD has a particular advantage as SNPs may be used for the identification of donor- and recipient-derived cells, which can further aid in the detection of residual leukemic cell populations.175

Going beyond mere identification of malignant cells, multi-omics platforms are increasingly becoming available as technologies to define the transcriptional states of individual leukemia clones. Among the pioneering works are studies by Nam et al.53 and van Galen et al.54 which both provided approaches for the integrated detection of somatic mutations and gene expression profiles in a high-throughput manner (“genotyping of transcriptomes” – GoT). These studies could demonstrate that MPN clones harboring CALR mutations gained a selective advantage over other clones and exhibited upregulated NF-κB signaling, tracked six differentiation states of AML from HSC-like to dendritic-like cells, and performed differential gene expression analyses between normal and malignant hematopoiesis. Central challenges of GoT are the dependence on sufficient expression levels of targeted genes and the genomic location of many somatic mutations in the middle of their respective transcripts, which makes identification with short-read sequencing difficult and leads to many cells without genotyping information. Several solutions have been proposed to improve the success rate of defining the transcriptional states of genetically defined leukemia cells. Petti et al. have demonstrated that, by analyzing private, non-recurrent somatic mutations identified by parallel WGS, it is possible to genotype a large number of scRNA-seq profiles, even without additional targeted sequencing.176 Another possibility is the employment of long-read sequencing, which enables the detection of mutations distant from the ends of a transcript. The “nanoranger” protocol leverages the much-improved sequencing accuracy of Oxford Nanopore sequencing.177 Finally, a potential solution is the combination of scDNA-seq with scRNA-seq, as demonstrated by Rodriguez-Meira et al.,178 albeit at the cost of a more complex workflow.

Regarding translational applications, all these approaches have in common the potential to perform leukemia tracking in combination with sensitive detection of resistance-mediating gene expression profile changes. As the throughput of single-cell sequencing increases, this may be used clinically to track the emergence of immune escape after effective immunotherapy before an overt relapse. An example could be early detection of CD19neg leukemia relapse after CAR T cell therapy at the time of MRD.

Mitochondrial DNA mutations

Although the focus of single-cell lineage-tracing efforts in blood malignancies has been on somatic nuclear DNA mutations, in recent years mitochondrial DNA (mtDNA) mutations have gained increasing attention as a natural barcoding system that additionally enables to establish clonal relationships with healthy tissues without the need for prior synthetic barcoding.50,179–181 In contrast to somatic nuclear mutations, mtDNA mutations occur frequently in almost all cells and thus potentially greatly expand opportunities for lineage tracing. Given its cell division-independent replication, mtDNA has a mutation rate that is 10 – 100x higher than nuclear genomic DNA.182 Its circular structure, short total length of approximately 16.6 kb, and high copy number of 100 – 1000 per cell183–185 make mtDNA ideal for high-coverage single-cell readouts and confident de novo variant calling.

Due to the unique non-chromatinized state of mtDNA, its mutations can be well-detected using a modified single-cell ATAC-sequencing protocol (mtscATAC-seq), which provides information on genetic lineage and cell states.180 The first demonstration of the potential of mtDNA mutation analysis with mtscATAC-seq to dissect longitudinal clonal evolution was provided in CLL, where Penter et al. used mtDNA mutational profiles to dissect the effects of chemoimmunotherapy or allogeneic HSCT on leukemia cell subpopulation. Changes in mtDNA mutations correlated with these therapeutic bottlenecks and subclones with distinct chromatin accessibility profiles could be identified.181 This opens up the prospect of defining subclones below the level of recurrent somatic mutations and, thus, potentially finer dissection of heterogeneous leukemia populations. Poos et al. have provided another demonstration of this concept, using mitochondrial DNA mutations to track evolving subclones in MM throughout therapy.186

In the non-transformed context, mtDNA mutations are also useful markers of clonal ancestries that enable to address questions of tissue regeneration, for which hepatocytes are a model system due to their unique ability to dedifferentiate, expand, and redifferentiate.187,188 Passman et al. have demonstrated this approach by tracking spatially restricted clonal expansion among hepatocytes based on detecting mtDNA mutations.189 These results indicate that mtDNA mutations may also have great potential for the study of premalignant states that precede blood malignancies, for example, by dissecting clonal hematopoiesis below the level of individual driver mutations, as shown by Miller et al. in one selected case.190

One central question in this regard is how mitochondrial and somatic nuclear DNA mutations relate. Studies have addressed this by combining their detection in the same cell.191 Velten et al. have identified nuclear and mitochondrial single-nucleotide variants (SNVs) from scRNA-seq profiles in the bone marrow of AML.56 They could show that both mitochondrial and somatic nuclear DNA mutations provided complementary information for the identification of healthy and malignant hematopoietic clones and were able to distinguish preleukemic from leukemic cells. Developing this approach further, the group developed ‘CloneTracer’, an analytical framework that integrates mtDNA and somatic nuclear mutations based on Bayesian statistics to also correct for dropouts and false positive rates in (sub﻿-﻿)clone identification.55 Applying this method enabled the tracking of AML differentiation states, including those in the erythroid compartment, and the definition of aberrant surface marker expression that may enable improved identification of AML based on flow cytometry.

While mtDNA mutations provide novel avenues to the study of clonal evolution in blood malignancies, their unique genetics may come with specific challenges and opportunities to investigate aspects of mitochondrial biology. These include the potential to investigate the horizontal mitochondria transfer between cells, understand mechanisms of negative selection of mtDNA mutations that convey a competitive disadvantage,192 quantify the stochastic distribution of mitochondria amongst daughter cells during cell division and convergence of independent mutational events within the confined space of the mitochondrial genome,193 which will require further studies that perform side-by-side tracking of somatic nuclear and mtDNA mutations.

Challenges and outlook

Single-cell sequencing studies of immune and malignant cells in blood malignancies provide deep insights into the heterogeneity of both compartments from a single sample. With the maturation of the underlying assays and the increasing sizes of study cohorts that now match those of many bulk sequencing efforts, single-cell sequencing studies are gradually becoming the workhorse of hematologic translational research. Given the growing range of modalities that can be co-detected in a single cell,194 including methods for recording spatial information at high resolution, analyzing these rich single-cell datasets is increasingly a substantial bottleneck. An important future direction will, therefore, be the development of standardized tools that streamline recurrent analytical steps, such as the exploration of immune repertoire data or the analysis of genetic data obtained from single-cell profiles and, perhaps, even analytical approaches that leverage artificial intelligence. Similarly, with the many possibilities of what can be measured, an important question is also what should be measured. For example, while numerous efforts have been made to describe T cell phenotypes in peripheral blood associated with clinical outcomes, focusing on rare circulating antigen-specific or tissue-resident T cells may be of higher yield. Likewise, while single-cell studies of diagnostic or relapsed leukemia samples with high disease burden have documented clonal heterogeneity, it may be rewarding to start focusing on MRD+ disease after immunotherapeutic bottlenecks to better understand what enables the persistence of residual leukemia cells.

Finally, as the costs of high-throughput single-cell sequencing are expected to drop in the coming years, and assays are developed that do not depend on sophisticated microfluidics devices,195 the prospect of bringing individualized, prospective immune and leukemia single-cell monitoring into the clinic is a real possibility. One example for such a translational application may be an integrated post-transplant monitoring that will provide information on engraftment across the various immune cell compartments, tracking of residual recipient-derived hematopoiesis and, most importantly, detection of any emergence of immune escape variants, such as residual leukemia cells that downregulate HLA presentation or increase their expression of immune checkpoint molecules, all from the same single-cell dataset. Provided a streamlined analytical pipeline can be established, this may be an elegant approach to survey all these aspects in one unified single-cell assay and could meaningfully impact genomics-guided patient care.

Conflict of Interest

The Broad Institute of MIT and Harvard has filed patent applications relating to the use of technologies for detecting mitochondrial DNA mutations, in which L.S.L. is named as an inventor (US patent applications 17/251,451 and 17/928,696). L.S.L. is a consultant to Cartography Biosciences. The other authors declare no competing financial interests.

Author Contributions

A.C.R. contributed to the section on tracking clonal evolution and figure 5. L.S.L. reviewed the manuscript. L.P. designed figures and wrote the manuscript.

Acknowledgments

L.S.L. is supported by the NIH (UM1 HG012076), the Hector Fellow Academy, the Paul Ehrlich Foundation, an Emmy Noether fellowship (LU 2336/2-1) and grants by the German Research Foundation (DFG, LU 2336/3-1, LU 2336/6-1, STA 1586/5-1, TRR241, SFB1588). L.P. is a Scholar of the American Society of Hematology, a participant in the BIH Charité Digital Clinician Scientist Program funded by the DFG, the Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health at Charité (BIH), and receives funding support by the Max-Eder program of the German Cancer Aid (Deutsche Krebshilfe), the DKMS John Hansen Research Grant, and the Else Kröner-Fresenius-Stiftung (2023_EKEA.102).

Figures 1-3 contain visual elements that were created with BioRender.com.
==== Refs
Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin N Engl J Med Fefer A. Cheever M. A. Thomas E. D. et al 1979
300 7 333 337 10.1056/NEJM197902153000702 366408
Marrow Transplantation for Treatment of Aplastic Anemia New England Journal of Medicine Storb R. Prentice R.L. Thomas E.D. 1977
296 2 61 66 10.1056/NEJM197701132960201 136605
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia New England Journal of Medicine Maude S.L. Frey N. Shaw P.A.. 2014
371 16 1507 1517 10.1056/NEJMoa1407222 25317870
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma New England Journal of Medicine Raje N. Berdeja J. Lin Y. 2019
380 18 1726 1737 10.1056/NEJMoa1817226 31042825
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia New England Journal of Medicine Kantarjian H. Stein A. Gökbuget N. 2017
376 9 836 847 10.1056/NEJMoa1609783 28249141
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma New England Journal of Medicine Chari A. Minnema M. C. Berdeja J. G. 2022
387 24 2232 2244 10.1056/NEJMoa2204591 36507686
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma New England Journal of Medicine Ansell S.M. Lesokhin A.M. Borrello I.. 2015
372 4 311 319 10.1056/NEJMoa1411087 25482239
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia Nat Biotechnol Gottschlich A. Thomas M. Grünmeier R. 2023
10.1136/jitc-2022-ITOC9.57
Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets Blood Cieri N. Hookeri N. Stromhaug K. 2022
140 Supplement 1 4762 4764 10.1182/blood-2022-162841
CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia J Clin Invest Biernacki M. A. Foster K. A. Woodward K. B. 130 10 5127 5141 10.1172/JCI137723 32831296
Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia Blood Sweeney C. Mickute G. Gupta K. et al 2022
140 Supplement 1 1576 1578 10.1182/blood-2022-166918 36201333
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting J Clin Invest Penter L. Wu C. J. 2020
130 4 1595 1607 10.1172/JCI129209 31985488
Status quo in flow-through cytometry J Histochem Cytochem Fulwyler M. J. 1974
22 7 605 606 10.1177/22.7.605 4137205
Mass Cytometry: Single Cells, Many Features Cell Spitzer M. H. Nolan G. P. 2016
165 4 780 791 10.1016/j.cell.2016.04.019 27153492
High-throughput and single-cell T cell receptor sequencing technologies Nat Methods Pai J. A. Satpathy A. T. 2021
18 8 881 892 10.1038/s41592-021-01201-8 34282327
Practical guidelines for B-cell receptor repertoire sequencing analysis Genome Medicine Yaari G. Kleinstein S.H. 2015
7 1 121 10.1186/s13073-015-0243-2 26589402
Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation Acta Haematol Thiede C. Bornhäuser M. Ehninger G. 2004
112 1–2 16 23 10.1159/000077555 15179000
Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification Molecular & Cellular Proteomics Ren A.H. Diamandis E.P. Kulasingam V. 2021
20 100155 10.1016/j.mcpro.2021.100155 34597790
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin Blood Schmalbrock L. K. Dolnik A. Cocciardi S. 2021
137 22 3093 3104 10.1182/blood.2020007626 33598693
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics Nat Commun Morita K. Wang F. Jahn K.. 2020
11 1 5327 10.1038/s41467-020-19119-8 33087716
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation New England Journal of Medicine Vago L. Perna S. K. Zanussi M.. 2009
361 5 478 488 10.1056/NEJMoa0811036 19641204
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia Nature Gaiti F. Chaligne R. Gu H.. 2019
569 7757 576 580 10.1038/s41586-019-1198-z 31092926
Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity Frontiers in Genetics Goldman S. L. Hassan C. Khunte M.. 2019
10 23 10.3389/fgene.2019.00133 30881373
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation New England Journal of Medicine Christopher M. J. Petti A. A. Rettig M. P. et al 2018
379 24 2330 2341 10.1056/NEJMoa1808777 30380364
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation Nature Medicine Toffalori C. Zito L. Gambacorta V.. 2019
25 4 603 611 10.1038/s41591-019-0400-z
Methods and applications for single-cell and spatial multi-omics Nat Rev Genet Vandereyken K. Sifrim A. Thienpont B. Voet T. 2023
24 8 494 515 10.1038/s41576-023-00580-2 36864178
Single-cell multiomics: technologies and data analysis methods Exp Mol Med Lee J. Hyeon D. Y. Hwang D. 2020
52 9 1428 1442 10.1038/s12276-020-0420-2 32929225
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome Transplantation and Cellular Therapy Guillaume T. Thépot S. Peterlin P. 2021
27 10 839.e1 839.e6 10.1016/j.jtct.2021.06.029
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors Ther Adv Hematol Liberatore C. Stanghellini M. T. L. Lorentino F.. 2022
13 20406207221090882 10.1177/20406207221090882 35747461
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15 Bone Marrow Transplant Hell S. Jentzsch M. Franke G.-N.. 2022
57 5 824 826 10.1038/s41409-022-01609-6 35181744
Navigating preemptive and therapeutic donor lymphocyte infusions in advanced myeloid malignancies by high-sensitivity chimerism analysis Front Oncol Stadler M. Venturini L. Bünting I.. 2022
12 867356 10.3389/fonc.2022.867356 36059667
FACS single-cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells European Journal of Immunology Penter L. Dietze K. Bullinger L.. 2018
48 7 1248 1250 10.1002/eji.201847507 29537492
Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer OncoImmunology Penter L. Dietze K. Ritter J. 2019
8 6 e1586409 10.1080/2162402X.2019.1586409 31069154
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma Cancer Immunology Research Welters C. Lammoglia Cobo M. F. Stein C. A.. 2022
10 11 1407 1419 10.1158/2326-6066.CIR-22-0434 36122410
Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow Cancer Immunol Res Hansmann L. Han A. Penter L. Liedtke M. Davis M.M. 2017
5 9 744 754 10.1158/2326-6066.CIR-17-0012 28768640
Killer Cell Immunoglobulin-Like Receptors (KIR) Typing By DNA Sequencing Methods Mol Biol Hou L. Chen M. Steiner N. 2012
882 431 468 10.1007/978-1-61779-842-9_25 22665249
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) Eur J Immunol Cossarizza A. Chang H.-D. Radbruch A. 2019
49 10 1457 1973 10.1002/eji.201970107 31633216
Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry JCI Insight Oetjen K. A. Lindblad K. E. Goswami M.. 2018
3 23 10.1172/jci.insight.124928 30518681
Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states Nat Immunol Triana S. Vonficht D. Jopp-Saile L. 2021
22 12 1577 1589 10.1038/s41590-021-01059-0 34811546
The Human Cell Atlas bone marrow single-cell interactive web portal Experimental Hematology Hay S. B. Ferchen K. Chetal K. Grimes H. L. Salomonis N. 2018
68 51 61 10.1016/j.exphem.2018.09.004 30243574
Comprehensive Integration of Single-Cell Data Cell Stuart T. Butler A. Hoffman P.. 2019
177 7 1888 1902.e21 10.1016/j.cell.2019.05.031 31178118
cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies Nat Commun Pedersen C. B. Dam S. H. Barnkob M. B.. 2022
13 1 1698 10.1038/s41467-022-29383-5 35361793
Benchmarking atlas-level data integration in single-cell genomics Nat Methods Luecken M. D. Büttner M. Chaichoompu K. 2022
19 1 41 50 10.1038/s41592-021-01336-8 34949812
Large-scale simultaneous measurement of epitopes and transcriptomes in single cells Nat Methods Stoeckius M. Hafemeister C. Stephenson W.. 2017
14 9 865 868 10.1038/nmeth.4380 28759029
Multiplexed quantification of proteins and transcripts in single cells Nat Biotechnol Peterson V. M. Zhang K. X. Kumar N. 2017
35 10 936 939 10.1038/nbt.3973 28854175
High-throughput and high-dimensional single-cell analysis of antigen-specific CD8+ T cells Nat Immunol Ma K. Y. Schonnesen A. A. He C. 2021
22 12 1590 1598 10.1038/s41590-021-01073-2 34811538
A framework for highly multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity Science Advances Zhang W. Hawkins P.G. He J. 2021
7 20 eabf5835 10.1126/sciadv.abf5835 33990328
Exploring tissue architecture using spatial transcriptomics Nature Rao A. Barkley D. França G.S. Yanai I. 2021
596 7871 211 220 10.1038/s41586-021-03634-9 34381231
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia Blood Ahn I. E. Underbayev C. Albitar A. 2017
129 11 1469 1479 10.1182/blood-2016-06-719294 28049639
Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics Cell Ludwig L. S. Lareau C. A. Ulirsch J. C. 2019
176 6 1325 1339.e22 10.1016/j.cell.2019.01.022 30827679
Natural Barcodes for Longitudinal Single-cell Tracking of Leukemic and Immune Cell Dynamics Front Immunol Penter L. Gohil S. H. Wu C. J. 2021
12 788891 10.3389/fimmu.2021.788891 35046946
Single-cell mutation analysis of clonal evolution in myeloid malignancies Nature Miles L. A. Bowman R. L. Merlinsky T. R.. 2020
587 7834 477 482 10.1038/s41586-020-2864-x 33116311
Somatic mutations and cell identity linked by Genotyping of Transcriptomes Nature Nam A. S. Kim K.-T. Chaligne R. 2019
571 7765 355 360 10.1038/s41586-019-1367-0 31270458
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity Cell van Galen P. Hovestadt V. Wadsworth M. H., II 2019
176 6 1265 1281.e24 10.1016/j.cell.2019.01.031 30827681
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia Cell Stem Cell Beneyto-Calabuig S. Merbach A.K. Kniffka J.-A. 2023
30 5 706 721.e8 10.1016/j.stem.2023.04.001 37098346
Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics Nat Commun Velten L. Story B. A. Hernández-Malmierca P. 2021
12 1 1366 10.1038/s41467-021-21650-1 33649320
Paired Donor and Recipient Immunophenotyping in Allogeneic Hematopoietic Stem Cell Transplantation: A Cellular Network Approach Front Immunol Wittenbecher F. Lesch S. Kolling S.. 2022
13 874499 10.3389/fimmu.2022.874499 35677053
Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation Front Immunol Ogonek J. Kralj Juric M. Ghimire S.. 2016
7 507 10.3389/fimmu.2016.00507 27909435
Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse Blood Gournay V. Vallet N. Peux V. 2022
140 11 1305 1321 10.1182/blood.2022015522 35820057
Mass Cytometry and Topological Data Analysis Reveal Immune Parameters Associated with Complications after Allogeneic Stem Cell Transplantation Cell Rep Lakshmikanth T. Olin A. Chen Y.. 2017
20 9 2238 2250 10.1016/j.celrep.2017.08.021 28854371
Mitochondrial DNA Mutations Distinguish Individual Donor- and Recipient-Derived Immune Cells Following Matched Unrelated Allogeneic Stem Cell Transplantation Blood Penter L. Southard J. Li S. 2021
138 Supplement 1 1689 10.1182/blood-2021-145304
Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease J Clin Invest Divito S. J. Aasebø A. T. Matos T. R. 2020
130 9 4624 4636 10.1172/JCI129965 32516138
Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation Science Immunology Huo Y. Wu L. Pang A. 2023
8 81 eabn6429 10.1126/sciimmunol.abn6429 36930730
Single-cell clonal tracking of persistent T-cells in allogeneic hematopoietic stem cell transplantation Frontiers in Immunology Obermayer B. Keilholz L. Conrad T.. 2023
14 10.3389/fimmu.2023.1114368 36860867
Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment Nat Commun Luo Y. Xu C. Wang B. 2021
12 1 3913 10.1038/s41467-021-24213-6 34162888
The vast majority of CLA+ T cells are resident in normal skin J Immunol Clark R. A. Chong B. Mirchandani N. 2006
176 7 4431 4439 10.4049/jimmunol.176.7.4431 16547281
Long-term skin-resident memory T cells proliferate in situ and are involved in human graft-versus-host disease Science Translational Medicine Strobl J. Pandey R. V. Krausgruber T.. 2020
12 570 eabb7028 10.1126/scitranslmed.abb7028 33208504
Haplotype-based variant detection from short-read sequencing Garrison E. Marth G. 2012

TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data Nat Methods Song L. Cohen D. Ouyang Z. 2021
18 6 627 630 10.1038/s41592-021-01142-2 33986545
Human skin-resident host T cells can persist long term after allogeneic stem cell transplantation and maintain recirculation potential Sci Immunol de Almeida G. P. Lichtner P. Eckstein G. 2022
7 67 eabe2634 10.1126/sciimmunol.abe2634 35089814
Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse Sci Transl Med DeWolf S. Elhanati Y. Nichols K.. 2023
15 706 eabq0476 10.1126/scitranslmed.abq0476 37494469
Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHD JCI Insight Poe J. C. Fang J. Zhang D. 8 11 e169732 10.1172/jci.insight.169732 37129971
High-sensitive spatially resolved T cell receptor sequencing with SPTCR-seq Nat Commun Benotmane J. K. Kueckelhaus J. Will P. 2023
14 1 7432 10.1038/s41467-023-43201-6 37973846
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response Immunity Liu S. Iorgulescu J. B. Li S.. 2022
55 10 1940 1952.e5 10.1016/j.immuni.2022.09.002 36223726
60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy Cancer Res Cieri N. Maurer K. Wu C.J. 2021
81 17 4373 4384 10.1158/0008-5472.CAN-21-0301 34108142
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation Leukemia Huuhtanen J. Adnan-Awad S. Theodoropoulos J. 2023
10.1038/s41375-023-02074-w 37919606
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect Science Translational Medicine Bachireddy P. Ennis C. Nguyen V.N. 2020
12 561 eabb7661 10.1126/scitranslmed.abb7661 32938797
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion Blood Bachireddy P. Hainz U. Rooney M. 2014
123 9 1412 1421 10.1182/blood-2013-08-523001 24357730
Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy bioRxiv Maurer K. Park C. Y. Mani S.. 2024 2024.02.09.579677
AML relapse after a TIGIT race Blood Penter L. Wu C. J. 2022
140 11 1189 1191 10.1182/blood.2022017614 36107461
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia Blood Advances Shahid S. Ceglia N. Le Luduec J.-B. 2023
7 17 5069 5081 10.1182/bloodadvances.2022009468 37327118
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study) JCO Kröger N. Sockel K. Wolschke C.. 2021
39 30 3318 3327 10.1200/JCO.20.02724
The Graft-Versus-Leukemia Effect in AML Front Oncol Sweeney C. Vyas P. 2019
9 1217 10.3389/fonc.2019.01217 31803612
Ipilimumab for Patients with Relapse after Allogeneic Transplantation N Engl J Med Davids M. S. Kim H. T. Bachireddy P.. 2016
375 2 143 153 10.1056/NEJMoa1601202 27410923
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation Blood Penter L. Zhang Y. Savell A.. 2021
137 23 3212 3217 10.1182/blood.2021010867 33720354
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study Cancer Discov Daver N. Garcia-Manero G. Basu S. 2019
9 3 370 383 10.1158/2159-8290.CD-18-0774 30409776
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms Sci Transl Med Prestipino A. Emhardt A. J. Aumann K.. 2018
10 429
Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case Blood Adv Penter L. Gohil S. H. Huang T.. 2021
5 22 4701 4709 10.1182/bloodadvances.2021004335 34432868
Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings Blood Garcia J. S. Flamand Y. Penter L.. 2022 blood.2022017686
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation Blood Davids M. S. Kim H. T. Costello C.. 2020
135 24 2182 2191 10.1182/blood.2019004710 32478814
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation Biology of Blood and Marrow Transplantation Wang A. Y. Kline J. Stock W. 2020
26 5 1025 1027 10.1016/j.bbmt.2020.01.021 32018063
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML Blood Advances Zeidan A. M. Boss I. Beach C. L.. 2022
6 7 2219 2229 10.1182/bloodadvances.2021006138 34933333
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings Blood Garcia J. S. Flamand Y. Penter L. 2023
141 15 1884 1888 10.1182/blood.2022017686 36332187
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease Blood Penter L. Liu Y. Wolff J.O. 2023
141 15 1817 1830 10.1182/blood.2022018246 36706355
A multidimensional analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in the bone marrow of pediatric acute myeloid leukemia medRxiv Koedijk J. B. van der Werf I. Penter L.. 2023
2023.03.03.23286485 10.1101/2023.03.03.23286485 37961528
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response Br J Haematol Apostolova P. Kreutmair S. Toffalori C.. 2023 10.1111/bjh.19007
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia J Immunother Cancer Goswami M. Gui G. Dillon L. W. 2022
10 1 e003392 10.1136/jitc-2021-003392 35017151
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study Blood Brunner A. M. Esteve J. Porkka K. 2021
138 Supplement 1 244 10.1182/blood-2021-146039
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2 Future Oncology Zeidan A.M. Giagounidis A. Sekeres M.A.. 2023
19 9 631 642 10.2217/fon-2022-1237 37083373
Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS Blood Huuhtanen J. Brück O. Peltonen K.. 2021
138 801 10.1182/blood-2021-147150
CAR-T cell therapy: current limitations and potential strategies Blood Cancer J Sterner R. C. Sterner R. M. 2021
11 4 1 11 33414374
Long-term outcomes following CAR T cell therapy: what we know so far Nat Rev Clin Oncol Cappell K. M. Kochenderfer J. N. 2023
20 6 359 371 10.1038/s41571-023-00754-1 37055515
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Nat Med Deng Q. Han G. Puebla-Osorio N. 2020
26 12 1878 1887 10.1038/s41591-020-1061-7 33020644
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy Cancer Discovery Chen G.M. Chen C. Das R.K. 2021
11 9 2186 2199 10.1158/2159-8290.CD-20-1677 33820778
Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma Patients Clin Cancer Res Sarén T. Ramachandran M. Gammelgård G. 2023
29 20 4139 4152 10.1158/1078-0432.CCR-23-0178 37540566
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL Science Advances Bai Z. Woodhouse S. Zhao Z.. 2022
8 23 eabj2820 10.1126/sciadv.abj2820 35675405
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat Rev Drug Discov Depil S. Duchateau P. Grupp S. A. Mufti G. Poirot L. 2020
19 3 185 199 10.1038/s41573-019-0051-2 31900462
Latent human herpesvirus 6 is reactivated in CAR T cells Nature Lareau C. A. Yin Y. Maurer K.. 2023
623 7987 608 615 10.1038/s41586-023-06704-2 37938768
Confused about Confusion New England Journal of Medicine Spanjaart A.M. van der Valk F.M. van Rooijen G. Brouwer M.C. Kersten M.J. 2022
386 1 80 87 10.1056/NEJMcps2114818 34986289
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia N Engl J Med Maude S.L. Laetsch T.W. Buechner J. 2018
378 5 439 448 10.1056/NEJMoa1709866 29385370
Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy Int J Infect Dis Handley G. Khawaja F. Kondapi D.S. 2021
112 327 329 10.1016/j.ijid.2021.09.061 34600133
HHV-6 Encephalitis After Chimeric Antigen Receptor T-cell Therapy (CAR-T): 2 Case Reports and a Brief Review of the Literature Open Forum Infect Dis Rebechi M. T. Bork J. T. Riedel D. J. 2021
8 11 ofab470 10.1093/ofid/ofab470 34738024
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy Nat Commun Sheih A. Voillet V. Hanafi L.-A. 2020
11 1 219 10.1038/s41467-019-13880-1 31924795
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq Molecular Therapy Boroughs A.C. Larson R.C. Marjanovic N.D. 2020
28 12 2577 2592 10.1016/j.ymthe.2020.07.023 32755564
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells Nature Melenhorst J. J. Chen G. M. Wang M.. 2022
602 7897 503 509 10.1038/s41586-021-04390-6 35110735
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia Nat Med Anderson N. D. Birch J. Accogli T. et al 2023
29 7 1700 1709 10.1038/s41591-023-02415-3 37407840
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults Blood Gardner R. A. Finney O. Annesley C. 2017
129 25 3322 3331 10.1182/blood-2017-02-769208 28408462
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia Nat Med Orlando E. J. Han X. Tribouley C. 2018
24 10 1504 1506 10.1038/s41591-018-0146-z 30275569
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19 Leukemia Asnani M. Hayer K.E. Naqvi A.S. 2020
34 4 1202 1207 10.1038/s41375-019-0580-z 31591467
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy Blood Gardner R. Wu D. Cherian S. 2016
127 20 2406 2410 10.1182/blood-2015-08-665547 26907630
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity Nat Commun Jacoby E. Nguyen S. M. Fountaine T. J. et al 2016
7 1 12320 10.1038/ncomms12320 27460500
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy Cancer Discov Sotillo E. Barrett D. M. Black K. L. et al 2015
5 12 1282 1295 10.1158/2159-8290.CD-15-1020 26516065
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy Cancer Immunol Res Im N.G. Guillaumet-Adkins A. Wal M. 2022
10 9 1055 1068 10.1158/2326-6066.CIR-21-0626 35759797
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy Nat Commun Rabilloud T. Potier D. Pankaew S.. 2021
12 1 865 10.1038/s41467-021-21168-6 33558546
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy Nat Med Good Z. Spiegel J. Y. Sahaf B.. 2022
28 9 1860 1871 10.1038/s41591-022-01960-7 36097223
TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma Mol Cancer Jiang V. C. Hao D. Jain P. 2022
21 1 185 10.1186/s12943-022-01655-0 36163179
Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma Cancer Discov Jackson Z. Hong C. Schauner R. 2022
12 8 1886 1903 10.1158/2159-8290.CD-21-1586 35554512
Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages Cancer Discovery Wilson T. L. Kim H. Chou C.-H. 2022
12 9 2098 2119 10.1158/2159-8290.CD-21-1508 35792801
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review Transplant Cell Ther Grant S.J. Grimshaw A.A. Silberstein J.. 2022
28 6 294 302 10.1016/j.jtct.2022.03.006 35288347
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies CNS Drugs Gust J. Taraseviciute A. Turtle C. J. 2018
32 12 1091 1101 10.1007/s40263-018-0582-9 30387077
Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells Cell Rep Med Strati P. Li X. Deng Q. 2023
4 8 101158 10.1016/j.xcrm.2023.101158 37586321
BCMA-targeted immunotherapy for multiple myeloma J Hematol Oncol Yu B. Jiang T. Liu D. 2020
13 1 125 10.1186/s13045-020-00962-7 32943087
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Leukemia Shah N. Chari A. Scott E. Mezzi K. Usmani S.Z. 2020
34 4 985 1005 10.1038/s41375-020-0734-z 32055000
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Nat Med Da Vià M. C. Dietrich O. Truger M. 2021
27 4 616 619 10.1038/s41591-021-01245-5 33619368
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma Nat Commun Samur M. K. Fulciniti M. Aktas Samur A.. 2021
12 1 868 10.1038/s41467-021-21177-5 33558511
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Nat Med Lee H. Ahn S. Maity R. 2023
29 9 2295 2306 10.1038/s41591-023-02491-5 37653344
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice Haematologica Zhou X. Rasche L. Kortüm K. M. Mersi J. Einsele H. 2022
108 4 958 968 10.3324/haematol.2020.266841 36263838
Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma Leukemia Leipold A. M. Werner R. A. Düll J.. 2023
37 3 650 658 10.1038/s41375-023-01824-0 36720972
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia Mol Ther Li X. Guo X. Zhu Y.. 2021
29 2 645 657 10.1016/j.ymthe.2020.11.028 33278564
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing Exp Hematol Oncol Li W. Zhang B. Cao W. 2023
12 1 44 10.1186/s40164-023-00402-5 37158921
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma Blood Cancer Discovery Dhodapkar K. M. Cohen A. D. Kaushal A. 2022
3 6 490 501 10.1158/2643-3230.BCD-22-0018 36026513
Somatic mosaicism in healthy human tissues Trends Genet De S. 2011
27 6 217 223 10.1016/j.tig.2011.03.002 21496937
Pathogenic Mechanisms of Somatic Mutation and Genome Mosaicism in Aging Cell Vijg J. Dong X. 2020
182 1 12 23 10.1016/j.cell.2020.06.024 32649873
Clonal hematopoiesis in human aging and disease Science Jaiswal S. Ebert B. L. 2019
366 6465 eaan4673 10.1126/science.aan4673 31672865
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification Blood Strati P. Shanafelt T. D. 2015
126 4 454 462 10.1182/blood-2015-02-585059 26065657
Monoclonal Gammopathy of Undetermined Significance Neoplastic Diseases of the Blood Kyle R.A. Rajkumar S.V. 2013
751 785 10.1007/978-1-4614-3764-2_38
Mutations driving CLL and their evolution in progression and relapse Nature Landau D. A. Tausch E. Taylor-Weiner A. N. 2015
526 7574 525 530 10.1038/nature15395 26466571
Molecular map of chronic lymphocytic leukemia and its impact on outcome Nat Genet Knisbacher B. A. Lin Z. Hahn C. K. 2022
54 11 1664 1674 10.1038/s41588-022-01140-w 35927489
Genomic Classification and Prognosis in Acute Myeloid Leukemia New England Journal of Medicine Papaemmanuil E. Gerstung M. Bullinger L.. 2016
374 23 2209 2221 10.1056/NEJMoa1516192 27276561
The genomic landscape of pediatric acute lymphoblastic leukemia Nat Genet Brady S. W. Roberts K. G. Gu Z. 2022
54 9 1376 1389 10.1038/s41588-022-01159-z 36050548
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups Leukemia Bolli N. Biancon G. Moarii M. 2018
32 12 2604 2616 10.1038/s41375-018-0037-9 29789651
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma N Engl J Med Schmitz R. Wright G. W. Huang D. W. et al 2018
378 15 1396 1407 10.1056/NEJMoa1801445 29641966
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations Haematologica Agathangelidis A. Ljungström V. Scarfò L. 2018
103 5 865 873 10.3324/haematol.2017.177212 29449433
Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome Leukemia Barrio S. Shanafelt T.D. Ojha J. et al 2017
31 1 170 176 10.1038/leu.2016.172 27469216
Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease J Mol Cell Cardiol Marnell C. S. Bick A. Natarajan P. 2021
161 98 105 10.1016/j.yjmcc.2021.07.004 34298011
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations Blood Lindsley R. C. Mar B. G. Mazzola E.. 2015
125 9 1367 1376 10.1182/blood-2014-11-610543 25550361
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med Cancer Genome Atlas Research Network Ley T. J. Miller C.. 2013
368 22 2059 2074 10.1056/NEJMoa1301689 23634996
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma Haematologica Mikulasova A. Wardell C. P. Murison A.. 2017
102 9 1617 1625 10.3324/haematol.2017.163766 28550183
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia Cell Landau D. A. Carter S. L. Stojanov P. 2013
152 4 714 726 10.1016/j.cell.2013.01.019 23415222
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy Nature Communications Landau D. A. Sun C. Rosebrock D. 2017
8 1 2185 10.1038/s41467-017-02329-y 29259203
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature Ding L. Ley T. J. Larson D. E. et al 2012
481 7382 506 510 10.1038/nature10738 22237025
Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets Blood Adv Stratmann S. Yones S.A. Mayrhofer M. 2021
5 3 900 912 10.1182/bloodadvances.2020003709 33560403
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma Blood Spina V. Bruscaggin A. Cuccaro A. 2018
131 22 2413 2425 10.1182/blood-2017-11-812073 29449275
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides Blood Egan J. B. Shi C.-X. Tembe W.. 2012
120 5 1060 1066 10.1182/blood-2012-01-405977 22529291
Exome sequencing in tracking clonal evolution in multiple myeloma following therapy | Leukemia
Accuracy of Next Generation Sequencing Platforms Next Gener Seq Appl Fox E. J. Reid-Bayliss K. S. Emond M. J. Loeb L. A. 2014
1 1000106 10.4172/2469-9853.1000106 25699289
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis Leukemia Arends C. M. Galan-Sousa J. Hoyer K.. 2018
32 9 1908 1919 10.1038/s41375-018-0047-7 29491455
High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics Genome Res Pellegrino M. Sciambi A. Treusch S. et al 2018
28 9 1345 1352 10.1101/gr.232272.117 30087104
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia Blood Albertí-Servera L. Demeyer S. Govaerts I. 2021
137 6 801 811 10.1182/blood.2020006996 32812017
Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia Leukemia De Bie J. Demeyer S. Alberti-Servera L. et al 2018
32 6 1358 1369 10.1038/s41375-018-0127-8 29740158
Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia Genome Res Wang L. Fan J. Francis J. M. et al 2017
27 8 1300 1311 10.1101/gr.217331.116 28679620
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations Journal of Clinical Oncology Lannes R. Samur M. Perrot A.. 2023
41 9 1695 1702 10.1200/JCO.21.01987 36343306
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma Blood Maia C. Puig N. Cedena M.-T. 2020
135 26 2375 2387 10.1182/blood.2019003382 32299093
Genetic interrogation of circulating multiple myeloma cells at single-cell resolution Sci Transl Med Lohr J. G. Kim S. Gould J. 2016
8 363 363ra147 10.1126/scitranslmed.aac7037 27807282
Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation Blood Biernacki M. A. Waltner O. Kanaan S. B. 2022
140 Supplement 1 10215 10216 10.1182/blood-2022-171164
A general approach for detecting expressed mutations in AML cells using single-cell RNA-sequencing Nat Commun Petti A. A. Williams S. R. Miller C. A. 2019
10 1 3660 10.1038/s41467-019-11591-1 31413257
Integrative genotyping of cancer and immune phenotypes by long-read sequencing Nat Commun Penter L. Borji M. Nagler A. 2024
15 1 32 10.1038/s41467-023-44137-7 38167262
Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing Mol Cell Rodriguez-Meira A. Buck G. Clark S-A.. 2019
73 6 1292 1305.e8 10.1016/j.molcel.2019.01.009 30765193
Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA eLife Xu J. Nuno K. Litzenburger U. M. 8
Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling Nat. Biotechnol. Lareau C. A. Ludwig L. S. Muus C. 2021
39 4 451 461 32788668
Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history Cancer Discov Penter L. Gohil S. H. Lareau C.. 2021
11 3048 63 10.1158/2159-8290.CD-21-0276 34112698
Age-Related Accumulation of Somatic Mitochondrial DNA Mutations in Adult-Derived Human iPSCs Cell Stem Cell Kang E. Wang X. Tippner-Hedges R. 2016
18 5 625 636 10.1016/j.stem.2016.02.005 27151456
Random intracellular drift explains the clonal expansion of mitochondrial DNA mutations with age Am J Hum Genet Elson J. L. Samuels D. C. Turnbull D. M. Chinnery P. F. 2001
68 3 802 806 10.1086/318801 11179029
The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease Nat Rev Genet Stewart J. B. Chinnery P. F. 2015
16 9 530 542 10.1038/nrg3966 26281784
Mitochondrial DNA genetics and the heteroplasmy conundrum in evolution and disease Cold Spring Harb Perspect Biol Wallace D.C. Chalkia D. 2013
5 11 a021220 10.1101/cshperspect.a021220 24186072
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis Blood Poos A. M. Prokoph N. Przybilla M. J. 2023
142 19 1633 1646 10.1182/blood.2023019758 37390336
Hippo pathway activity influences liver cell fate Cell Yimlamai D. Christodoulou C. Galli G. G. 2014
157 6 1324 1338 10.1016/j.cell.2014.03.060 24906150
Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes Cell Stem Cell Tarlow B. D. Pelz C. Naugler W. E.. 2014
15 5 605 618 10.1016/j.stem.2014.09.008 25312494
Hepatocytes undergo punctuated expansion dynamics from a periportal stem cell niche in normal human liver J Hepatol Passman A. M. Haughey M. J. Carlotti E. 2023
79 2 417 432 10.1016/j.jhep.2023.03.044 37088309
Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations Nat Biotechnol Miller T. E. Lareau C. A. Verga J. A. 2022
40 7 1030 1034 10.1038/s41587-022-01210-8 35210612
Integrative Single-Cell Tracking of Clonal Evolution, Leukemia Phenotypes and Donor Engraftment Following Allogeneic Stem Cell Transplant Using Mitochondrial DNA Mutations Blood Penter L. Cieri N. Maurer K.. 2023
142 3580 10.1182/blood-2023-180113
Single-cell multi-omics of mitochondrial DNA disorders reveals dynamics of purifying selection across human immune cells Nat Genet Lareau C. A. Dubois S. M. Buquicchio F. A. et al 2023
55 7 1198 1209 10.1038/s41588-023-01433-8 37386249
Mitochondrial mutation, drift and selection during human development and ageing Chapman Michael Przybilla Moritz J. Lawson Andrew R. J.. 2023

Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells Nat Biotechnol Mimitou E. P. Lareau C. A. Chen K. Y. 2021
1 13 33376248
Microfluidics-free single-cell genomics with templated emulsification Nat Biotechnol Clark I.C. Fontanez K.M. Meltzer R.H. 2023
41 11 1557 1566 10.1038/s41587-023-01685-z 36879006
